华东医药：全资子公司收到瑞玛比嗪注射液药品注册证书

Core Viewpoint - The approval of the registration certificate for Remabizine injection by the National Medical Products Administration is a significant development for the company, indicating progress in its pharmaceutical offerings and potential future revenue growth [1] Company Summary - The company's wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received the registration certificate for Remabizine injection, which is an exogenous fluorescent tracer used in conjunction with MediBeacon Inc's equipment to assess patients' glomerular filtration rate [1] - The total direct investment in the development of Remabizine injection and the TGFR project amounts to approximately 273 million yuan [1] - The approval is not expected to have a major impact on the company's current financial status and operating results, but it is anticipated to have a positive effect on future performance [1]